3LABENZ J, PETERSEN K U, ROSCH W, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole [ J]. Aliment Pharmacol Ther,2003,17 (8) : 1015-1019.
4MIURA M. Enantioseleetive disposition of lansoprazole and rabeprazole in human plasma[ J ]. Yakugaku Zasshi,2006, 126(6) :395-402.
5KIM K A, KIM M J, PARK J Y, et al. Stereoselective me-tabolism of lansoprazole by human liver cytochrome P450 enzymes[J]. Drug Metab Dispos, 2003,31 (10) :1227- 1234.
6ISHIZAKI T, HORAI Y. Review article: eytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole [ J]. Aliment Pharmacol Ther, 1999, 13 ( Suppl 3) :27-36.
7MIURA M, KAGAYA H, TADA H, et al. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole [ J ]. Xenobiotica, 2006,36 ( 1 ) : 95-102.
8TRAN A, REY E, PONS G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children [ J ]. Clin Pharmacol Ther,2002,71 (5) :359-367.
9CROOM K F, SCOTT L J. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents[ J]. Drugs ,2005,65 ( 15 ) :2129-2135.
10GREMSE D, WINTER H, TOLIA V, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease[ J ]. J Pediatr Gastroenterol Nutr, 2002,35 ( Suppl 4 ) : 319-326.
二级参考文献17
1Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy [ J ]. Dig Liver Dis, 2003,35(10) :711-715.
2Malfertheiner P, Megraud F, O' Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2- 2000 Consensus Report [J]. Aliment Pharmacol Ther, 2002, 16 (2) :167-180.
3Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy [J]. Gastroenterology, 1998,115(5) :1272-1277.
4Ling TK, Cheng AF, Sung JJ, et al. An increase in Helicobacter pylori strains resistant to metronidasole : a five-year study [ J]. Helicobacter, 1996,1 ( 1 ) :57-61.
5Cammarota G, Cianci R, Cannissaro O, et al. Efficacy of two one- week rabeprasole/levofloxacin-based triple therapies for Helicobacter pylori infection [ J ]. Aliment Pharmacol Ther, 2000, 14 ( 10 ) : 1339-1343.
6Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori [ J]. Eur J Gastroenterol Hepatol, 2002,14 ( 12 ) : 1309 -1312.
7Peril F, Fests V, Merla A, et al. Randomised study of different ' second-line' therapies for Helicobaeter pylori infection after failure of the standard ' Masstricht triple therapy' [ J ]. Aliment Pharmaeol Ther, 2003,18(8) :815-820.
8叶任高.内科学 第5版[M].北京:人民卫生出版社,2001.810.
9邵明立.国家基本药物(西药)：第2版[M].北京：人民卫生出版社,2002.459.
10Lamouliatte H, Cayla R, Zerbib F, et al. Essai controle randomise comparant la bitherapie (Lansorazole a dose amoxicilline) a la tritherapie (Lansorazole a forte dose amoxycilline - clarithromycine) dans L'infection a Helicobacter pylori. Gastroenterol Chin Biol 1995;19(2):189.
